骨肉瘤是儿童青少年最常见恶性肿瘤，转移后5年存活率不足30％，诊断时是否伴肺转移是预测5年存活率关键指标。.长链非编码RNA是新发现的癌症调控因子，作为效应分子能更好标记肿瘤特征，针对它的治疗副作用较少，但其对骨肉瘤调控作用不清楚。NF-κB参与肿瘤发病的各个环节，针对该通路的靶向治疗是提高抗癌药物对骨肉瘤活性的有效方法。芯片检测发现人骨肉瘤组织中长链非编码RNA-SNHG6、NF-κB通路关键因子Ikkβ和XIAP显著上调。.本项目用CRISPR/Cas9技术敲除骨肉瘤细胞中SNHG6基因，在野生型及SNHG6敲除骨肉瘤细胞、原位和肺转移裸鼠骨肉瘤、SNHG6敲入小鼠模型中运用RT-PCR、Northern Blot、RIP、RNA EMSA、原位杂交、免疫组化等方法研究，揭示SNHG6激活NF-κB通路对骨肉瘤发病和转移的重要性，以及“芪重三七散”体内外抗骨肉瘤发病和肺转移的效应机制。

Osteosarcoma is a most common cancer in children and adolescents, the 5-year survival rate is less than 30% with metastasis. With pulmonary metastasis or not at diagnosis is the key prognosis indicator of the 5-year survival rate. .Long non-coding RNAs (lncRNAs) are newly discovered cancer regulatory factors, and can preferably mark the tumor inherent characteristics as the effector molecules, treatment targets lncRNAs will have fewer side effects, but their regulatory roles in osteosarcoma are not clear. NF-κB signaling is involved in many aspects of cancer incidence, and anticancer therapy targeted NF-κB pathway is an effective strategy for improving the activity of anti-osteosarcoma drugs. Expression of SNHG6 (lncRNA), Ikkβ and XIAP (NF-κB pathway critical factors) was significantly upregulated in human osteosarcoma tissues detected by lncRNAs microarray..In this project, SNHG6 gene knockout osteosarcoma cells will be generated by the CRISPR/Cas9 technique. RT-PCR, Northern Blot, RIP, RNA EMSA, in situ hybridization, immunohistochemistry, and other techniques will be used to study and reveal the importance of NF-κB activated by SNHG6 in osteosarcoma incidence and metastasis, and the effective mechanisms of "Qichong sanchi pulvis " for anti-osteosarcoma incidence and lung metastasis in vivo, with the models of wild-type and SNHG6 knockout osteosarcoma cells, in situ and lung metastasis osteosarcoma nude mice, SNHG6 knock-in mice.